Promoting Domestic Production of Critical Medicines The White House is pushing to see more state-of-the-art pharmaceutical manufacturing facilities within the United States to strengthen the supply of essential medicines. On May 5, 2025, the President signed an Executive Order titled “Regulatory Relief to Promote Domestic Production of Critical Medicines.” The goal of this order is […]
The Foci of PROSPR ARPA-H-SOL-25-125, PROSPR The PROSPR solicitation outlines a comprehensive, multi-year program structured around the development, validation, and deployment of novel health technologies. The program is divided into three primary technical areas (TAs), each addressing a critical component of healthspan extension: TA1 focuses on developing a PROSPR Intrinsic Capacity (IC) score that quantifies
Proactive Solutions for Prolonging Resilience Opportunity Announcement Read More »
Overview The Advanced Research Projects Agency for Health (ARPA-H) is dedicated to accelerating transformative health solutions by tackling some of the most pressing challenges in biomedical and healthcare innovation. As part of this mission, ARPA-H has launched Mission Office Innovative Solutions Openings (ISOs) that promote the development of health technologies that lie outside of the
ARPA-H Mission Office Innovative Solutions Openings (ISOs) Read More »
RAPID_SOL_25_119_FINAL Overview The Advanced Research Projects Agency for Health (ARPA-H) recently announced the newly approved program for Rare disease AI/ML for Precision Integrated Diagnostics (RAPID). The RAPID program aims to significantly improve outcomes for people with rare diseases by reducing diagnostic delays by ≥50%, decreasing misdiagnosis rates, and expanding access to diagnostics. Beyond benefitting the treatment experience of
RAPID Solicitation Read More »
ARPA_H_SOL_25_118_EHI_Solicitation (1) Emerging Health Innovators Solicitation: An Opportunity to Revolutionize Health Innovation The Advanced Research Projects Agency for Health (ARPA-H) has issued the Emerging Health Innovators (EHI) Initiative Solicitation (ARPA-H-SOL-25-118), a groundbreaking funding opportunity aimed at empowering both early-career researchers and community innovators to advance health and biomedical research. Through the EHI Initiative, ARPA-H seeks
Emerging Health Innovators (EHI) Initiative Read More »
RAPID_Special_Notice ARPA-H’s RAPID Program The Advanced Research Projects Agency for Health (ARPA-H) recently announced the newly approved program for Rare disease AI/ML for Precision Integrated Diagnostics (RAPID). This initiative aims to revolutionize the prolonged diagnostic odyssey faced by millions of rare disease patients worldwide. Utilizing fragmented datasets and state-of-the-art technologies, RAPID aims to democratize access
ARPA-H-SOL-25-125_Special_Notice ARPA-H’s PROSPR Program The Advanced Research Projects Agency for Health (ARPA-H) has announced the PROactive Solutions for Prolonging Resilience (PROSPR) initiative, an ambitious program designed to extend the healthspan of Americans by addressing the underlying causes of age-related health loss. By pioneering innovative interventions that target age-induced health deterioration, ARPA-H aims to revolutionize healthcare
ARPA-H launches groundbreaking funding opportunity The Advancing Clinical Trial Readiness (ACTR) Initiative, spearheaded by ARPA-H’s Resilient Systems Office (RSO), aims to revolutionize clinical trials by developing a decentralized, efficient, and accessible infrastructure. Overview of Solicitation The ACTR Initiative is focused on creating tools, networks, and infrastructure to enable decentralized and on-demand clinical trials. By integrating
ARPA-H-SN-25-119 (1) The Advanced Research Projects Agency for Health (ARPA-H) has launched the Emerging Health Innovators (EHI) Initiative, a transformative funding opportunity aimed at empowering early-career researchers and community-based innovators to revolutionize healthcare. To support this initiative, ARPA-H is holding a virtual Proposer’s Day on January 8th, 2025, from 11AM to 4PM EDT. Overview of
Emerging Health Innovators (EHI) Initiative Proposer’s Day Read More »
GLIDE_ISO_ARPA-H-SOL-24-111_Final_29_OCT_2024 Program Overview An estimated 10 million Americans are impacted by primary lymphatic diseases, and lymphatic dysfunction contributes to the pathophysiology of many widespread chronic illnesses. Despite the importance of the lymphatic system in disease, there are currently zero FDA-approved treatments, medical devices, or therapies specifically targeting lymphatic growth and function. To catalyze a future
Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) Read More »
ARPA-H_DECIDE-ET_Solicitation_DRAFT Overview of Exploration Topic Although Academic Medical Centers (AMCs) have developed many advanced therapies for rare and fatal diseases, access to AMCs remains limited due to outdated production methods and inadequate quality validation. To enhancing quality assurance technologies at AMCs, the Advanced Research Projects Agency for Health (ARPA-H) has initiated the Decentralized Engineering of
Decentralized Engineering of Cells Informed by Dynamic Evidence Exploration Topic Read More »
CATALYST_ISO_(DRAFT) Overview of CATALYST Solicitation Current in vivo animal model testing methods often fail to predict human drug safety accurately, leading to inefficiencies and high costs. The Health Science Futures (HSF) Office of the Advanced Research projects Agency for Health (ARPA-H) has introduced the CATALYST program to transform drug development. This program will foster the
